全球爱滋病毒疫苗市场规模：按类型、抗生素和地区分類的范围和预测

HIV疫苗市场规模及预测

预计 2024 年爱滋病毒疫苗市场规模将达到 3.5001 亿美元，到 2032 年将达到 5.6892 亿美元，2026 年至 2032 年的复合年增长率为 6.24%。

疫苗可以增强人体免疫系统，帮助预防疾病和感染。如果免疫系统对爱滋病毒（HIV）没有反应，它会产生抗体来减缓病毒的生长，但无法阻止其生长。通常，HIV疫苗是使用减毒或灭活病毒製成的。 HIV变异很快，因此，虽然疫苗针对的是某种病毒，但病毒本身的变异会导致疫苗失效。然而，用于治疗HIV的抗逆转录病毒药物仍是预防HIV感染的主要目标。全球HIV疫苗市场报告对市场进行了全面评估，全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

定义全球爱滋病毒疫苗市场

目前，全球约有3,500万人感染爱滋病毒（HIV），自爱滋病疫情爆发以来，约有3,000万人死于爱滋病。目前尚无已知的HIV感染后自行康復的病例。 HIV复製速度极快，目前全球存在多种不同类型的HIV，且新型病毒仍在不断繁殖。许多科学家正在努力了解免疫系统对HIV感染的具体反应。疫苗是最有效且最具成本效益的疾病预防手段之一。能够预防HIV感染或阻止其发展进程的疫苗将大大有助于对抗HIV。

疫苗在全球根除天花的努力中发挥了至关重要的作用，几乎根除了脊髓灰质炎，并逐渐降低了全球麻疹和百日咳等感染疾病的发生率。然而，一个问题是，HIV疫苗应该针对单一株开发，还是针对多种株结构设计？其目标是提供更有效的药物来根除这种病毒。这也引出了一个问题：HIV疫苗如何保护个人？疫苗可能无法预防感染，但可以阻止或减缓疾病的进展。

HIV预防教育和咨询是任何疫苗计画的重要组成部分，即使在疫苗发布后，仍需要持续有效的行为抑制计画。预防性HIV疫苗的成功研发将取决于全球公共和私营部门的参与。目前，没有任何政府或公司有足够的资源或勇气独自承担HIV疫苗的倡议。在公共部门，包括卫生、经济发展和国际发展在内的多个不同机构都需要开发HIV疫苗。

全球爱滋病疫苗市场概况

推动市场成长的主要因素是爱滋病毒感染率的上升。此外，人们对感染疾病的认识不断提高，也是推动市场成长前景乐观的因素。此外，为开发最有效的疫苗而持续投入研发活动，也推动了市场的成长。然而，疫苗相关的成本以及频繁的检测失败可能会减缓市场的成长。

市场趋势包括抗逆转录病毒疗法长效抑制剂（ATLAS）的开发。 ATLAS 是一种注射药物，目前正在进入市场，与其他药物相比，其疗效显着提高。 ATLAS 可作为现有 HIV 治疗方案的替代方案。

成长背后的驱动力之一是新产品上市和药物核准数量的不断增加。对爱滋病毒治疗研发的日益重视，推动了新药的创新，例如吉利德科学和VIIV Healthcare。此外，许多公司正在全球范围内建立战略合作伙伴关係并开发新药。

限制因素之一是缺乏治疗途径以及对爱滋病毒感染的无知，这可能会阻碍市场成长。儘管研发方面取得了许多进展，科学认知也不断提高，但许多爱滋病毒感染者仍无法及时获得治疗。目前，这种感染疾病仍然无法治疗方法。此外，许多人并不了解自己感染了感染疾病。根据 BioMed Central Ltd. 的一项调查，在 478 名参与企业中，三分之一的人报告为爱滋病毒阴性，这是阻碍市场参与企业成长的因素。

目录

第一章 全球HIV疫苗市场简介

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球HIV疫苗市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球HIV疫苗市场（按类型）

• 概述
• 化脓性寄生虫病
• 慢性甲沟炎
• 念珠菌寄生虫
• 急性寄生虫病
• 其他的

6. 全球HIV疫苗市场（按抗生素）

• 概述
• 双氯西林
• 夫西地酸软膏
• 庆大霉素软膏
• 莫匹罗星软膏
• 其他的

7. 全球HIV疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他的
  • 拉丁美洲
  • 中东和非洲

8. 全球HIV疫苗市场竞争格局

• 概述
• 各公司市场排名
• 重点发展策略

第九章 公司简介

• VIIV healthcare
• Antigen Express
• Gilead Sciences, Inc
• GlaxoSmithKline plc
• Merck Sharp & Dohme Corp.
• AbbVie Inc
• Mylan NV

第十章 重大进展

• 产品发布/开发
• 合併与收购
• 业务扩展
• 伙伴关係与合作

第十一章 附录

• 相关调查

HIV Vaccines Market Size And Forecast

HIV Vaccines Market size was valued at USD 350.01 Million in 2024 and is projected to reach USD 568.92 Million by 2032, growing at a CAGR of 6.24% from 2026 to 2032.

The immune system of the body can be boosted using the vaccine, which serves the protection against disease and infection. When the immune system fails to respond to HIV, it generates antibodies to slow the spread, it doesn't stop. Generally, HIV vaccines are made using weakened or killed viruses. HIV mutates quickly, and the vaccine targets the viruses in one form, the change in the virus results in vaccine failure. However, antiretroviral drugs anticipated for HIV, preventing HIV infection is still a primary goal. The Global HIV Vaccines Market report provides a holistic evaluation of the market. The report thoroughly analyzes important segments, trends, drivers, restraints, competitive landscape, and factors that play a substantial role in the market.

Global HIV Vaccines Market Definition

Worldwide, around 35 million people currently are infected with HIV, about 30 million people died due to AIDS infection since the beginning of the epidemic. There is no human example of clearing HIV infections naturally. HIV makes copies of it very quickly, different types of HIV exist in today's world, new types of viruses continue to rise. Many scientists are trying to understand the specific ways of the immune system which need to respond against HIV infection. Vaccines are among the foremost powerful and cost-effective disease prevention tools. The vaccine that could prevent HIV infection or stop the development of the disease would greatly support the fight against this disease.

Vaccines have been crucial in worldwide smallpox elimination efforts, have nearly eliminated polio, and have gradually reduced the incidence of infectious diseases like measles and pertussis across the world. However, the question arises whether the HIV vaccine should be developed for a single strain or should be designed for varied strain structures. The whole aim is to provide better medication for the eradication of this virus by any means. There are also questions that arise about how an HIV vaccine would protect the individuals and the vaccine might not be able to prevent the infections, but stop or delay progression to diseases, or can simply reduce the infectiousness of people who are infected with HIV.

HIV prevention education and counseling are important factors to be discussed in vaccine programs and after the release of a vaccine; there will be an ongoing need for effective behavioral hindrance programs. The successful development of a preventive HIV vaccine positively depends upon the involvement of both the private and public sectors across the world. Currently, no government or company has the resources and encouragement to take on the initiative of developing an HIV vaccine alone. Within the public sector, the development of the HIV vaccine is necessary for several different agencies, including concerns in health, economic development, and international development.

Global HIV Vaccines Market Overview

The main factor which contributes to fueling the market growth is the growing prevalence of HIV infection. Additionally, the increasing awareness among the population regarding the infection is another factor propelling a positive outlook on the growth of the market. Moreover, the continuous expenditure on research and development activities for the development of the most effective vaccination is driving market growth. However, the expense related to the vaccines and frequent trial failure can decline the market growth.

Some of the trends in the market include the development of antiretroviral therapy as a long-acting suppression (ATLAS) is an injectable formulation that has now entered the market and has increased the standard of care compared to the other drugs. It acts as an alternative option for the existing HIV drugs.

One of the driving factors is the increasing number of new product launches and rising drug approvals to boost growth. The growing emphasis on the research and development of HIV drugs has led to new drug innovations such as Gilead Sciences, VIIV healthcare, and many more. Furthermore, many companies are involved in strategic collaborations and new medications worldwide.

One of the restraining factors is a lack of access to treatment and unawareness of HIV infection which may hinder the growth. Despite many advancements in research and development and improved scientific understanding, many people infected with HIV do not have access to timely treatment. This infection still has no treatment available. Additionally, many people are still unaware of this infection. A study conducted by BioMed Central Ltd. reported that amongst the 478 participants, one-third of the participants were unaware of it, this is the reason which may hinder the growth of the market.

Global HIV Vaccines Market Segmentation Analysis

The Global HIV Vaccines Market is segmented on the basis of Type, Antibiotics, And Geography.

HIV Vaccines Market, By Type

• Pyogenic Paronychia
• Chronic Paronychia
• Candidal Paronychia
• Acute Paronychia
• Others

Based on Type, The market is bifurcated into Pyogenic Paronychia, Chronic Paronychia, Candidal Paronychia, Acute Paronychia, and Others.

HIV Vaccines Market, By Antibiotics

• Dicloxacillin
• Fusidic Acid Ointment
• Gentamicin Ointment
• Mupirocin Ointment
• Others

Based on Antibiotics, The market is bifurcated into Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment, Mupirocin Ointment, and Others.

HIV Vaccines Market, By Geography

• North America
• Europe
• The Asia Pacific
• Rest of the world

Based on Regional Analysis, The Global HIV Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Europe is expected to be the largest market during the forecast period. Due to the increase in HIV cases and the presence of a large number of HIV companies in the region. The rising strategic collaborations amongst the European Companies will improve drug availability, which will support the growth of the market.

Key Players

The "Global HIV Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are VIIV healthcare, Gilead Sciences, Inc, GlaxoSmithKline plc, Merck Sharp & Dohme Corp., AbbVie Inc, Mylan N.V, and many more. The competitive landscape section includes key development strategies, market share analysis, and market positioning analysis of the aforementioned competitors internationally.

Key Developments

• March 2021, Gilead Sciences Inc and Merck announced a collaboration agreement to co-develop and commercialize long-acting treatments for HIV. The companies plan to combine Gilead's investigational capsid inhibitor Lenacapavir and Merck's investigational nucleoside reverse translocation inhibitor to develop a two-drug regimen for HIV.
• January 2021, VIIV Healthcare received U.S FDA approval for Cabenuva, an injection indicated for the treatment of human immunodeficiency virus type 1 (HIV) for adults.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HIV VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HIV VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL HIV VACCINES MARKET, BY TYPE

• 5.1 Overview
• 5.2 Pyogenic Paronychia
• 5.3 Chronic Paronychia
• 5.4 Candidal Paronychia
• 5.5 Acute Paronychia
• 5.6 Others

6 GLOBAL HIV VACCINES MARKET, BY ANTIBIOTICS

• 6.1 Overview
• 6.2 Dicloxacillin
• 6.3 Fusidic Acid Ointment
• 6.4 Gentamicin Ointment
• 6.5 Mupirocin Ointment
• 6.6 Others

7 GLOBAL HIV VACCINES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL HIV VACCINES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 VIIV healthcare
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Antigen Express
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Gilead Sciences, Inc
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 GlaxoSmithKline plc
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Merck Sharp & Dohme Corp.
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 AbbVie Inc
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Mylan N.V
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research